U.K. warns against using arstolochia
This article was originally published in The Tan Sheet
Executive Summary
U.K. consumers should not use Xie Gan Wan pills, a Chinese product containing aristolochia, an unlicensed medicine the country banned in 1999, according to a Medicines and Healthcare products Regulatory Agency alert. MHRA identified a number of other products in recent years containing aristolochia, which can cause kidney failure. In 2004, California added aristolochic acid and other herbal remedies containing plant species of the genus aristolochia to the list of chemicals known to cause cancer (1"The Tan Sheet" July 12, 2004, In Brief)
You may also be interested in...
Aristolochic acid & Prop65
Aristolochic acid and "herbal remedies containing plant species of the genus Aristolochia" are added to California's list of chemicals known to cause cancer, the California Environmental Protection Agency's Office of Environmental Health Hazard Assessment announces. Effective July 9, the decision requires companies knowingly marketing products that contain the substance to include warning labels on product packaging. OEHHA says it received four public comments supporting the listing of these chemicals on the Prop 65 list of carcinogens. The proposal to include aristolochic acid on the list was announced in May (1"The Tan Sheet" May 31, 2004, p. 13)...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.